1

Greg Fenton Discusses Zentek’s 2024 Progress and Exclusive Aptamer Technology Rights

In a detailed interview with Tracy Weslosky, Greg Fenton, CEO and Director of Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN), shared insights into the company’s strategic progress and emerging opportunities, particularly emphasizing its work with aptamer technology. With an exclusive global license for innovative Aptamer-based platform technology developed by McMaster University, Zentek is pioneering advances in both diagnostic and therapeutic applications, underscoring its dedication to healthcare innovation. The company has made notable breakthroughs in COVID-19 therapeutics with its C19HBA aptamer, showing significant promise in preclinical trials by outperforming leading monoclonal antibodies. This success has paved the way for Phase 1 clinical trials for COVID-19 and exploration into other areas such as oncology, immunology, and neurology.

Fenton highlighted the positive reception from major pharmaceutical companies, reflecting a broad industry interest in Zentek’s aptamer technology. Additionally, Zentek’s ZenGUARD™ technology platform, known for its 99-percent anti-microbial activity, has been instrumental in enhancing the bacterial and viral filtration efficiency of surgical masks and HVAC systems. A recent study on ZenGUARD™ Enhanced Air Filters revealed its potential to offer significant energy, emission, and cost savings for commercial buildings, showcasing a scalable solution for improving indoor air quality and addressing climate change.

Throughout the conversation, Fenton articulated Zentek’s ambitious plans for partnerships and expansion, leveraging the favorable market conditions to boost the company’s visibility and impact. His vision for Zentek includes strategic partnerships, leveraging its proprietary technology, and a commitment to revolutionizing the approach to managing infectious diseases and enhancing environmental sustainability.

To access the complete interview, click here

Don’t miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by clicking here

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek, through its wholly-owned subsidiary Triera Biosciences Ltd., has a global exclusive license to the Aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

The Company is not making any express or implied claims that its aptamer technology has the ability to eliminate, cure or contain COVID-19 (or the SARS-CoV-2 coronavirus) at this time.

To learn more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorNews Inc.

This interview, which was produced by InvestorNews Inc. (“InvestorNews”), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this “presentation”) does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company’s profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.




Zentek’s Breakthrough Aptamer Platform Shows Promise in Fighting COVID-19

In a recent interview conducted by Tracy Weslosky of InvestorIntel, Greg Fenton, the CEO & Director of Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN), unveiled some thrilling developments surrounding the company’s revolutionary aptamer platform. With an exclusive global license from McMaster University, this groundbreaking platform has demonstrated remarkable success in pre-clinical animal model tests as a potential prophylactic or therapeutic for SARS-CoV-2, the virus responsible for the ongoing COVID-19 pandemic. Spearheaded by Dr. Yingfu Li’s team at McMaster, this platform harnesses a series of synthetic molecules known as aptamers, exhibiting a high affinity for the SARS-CoV-2 spike protein.

During the pre-clinical trials, groups of mice were treated with either the aptamer developed by Dr. Li’s team or a commercial monoclonal antibody before exposure to SARS-CoV-2. The outcomes were nothing short of impressive. Mice treated with the aptamer displayed minimal weight loss and showed no detectable viral burden in their lungs, while the control group experienced significant weight loss and a high lung viral load. Notably, the aptamers showcased efficacy on par with commercial monoclonal antibodies, effectively neutralizing the virus both in vitro and in vivo.

According to Greg, Dr. Li envisions the aptamer platform going beyond the treatment and prevention of current SARS-CoV-2 variants. The platform holds the potential to be a game-changer in the ongoing battle against COVID-19, even as new variants continue to emerge worldwide. This could mark a significant step forward in combatting the ever-evolving nature of the virus.

In the interview, Greg explains how aptamers have been proven to possess a favorable safety profile, as they are constructed from synthetic single-stranded DNA or RNA molecules using the same building blocks as human DNA or RNA. Greg Fenton expressed that the pre-clinical test results exceeded expectations, and the encouraging safety profile of aptamer-based therapeutics might accelerate the path to commercialization. This offers hope for faster and safer development of potential treatments and preventatives for COVID-19.

Zentek’s collaboration with McMaster University extends beyond its exclusive license, now encompassing all aptamer and DNAzyme uses, including diagnostics, therapeutics, and neutralization agents, not limited solely to SARS-CoV-2 applications. This expansion hints at the broader potential of the aptamer platform in addressing various medical challenges beyond COVID-19, promising exciting developments in the medical field.

Following these promising pre-clinical results, Zentek is actively working on formulating a comprehensive pre-clinical plan to develop a COVID-19 therapeutic or prophylactic based on Dr. Li’s aptamers. This represents a significant stride forward in the potential treatment and prevention of COVID-19, offering hope for effective solutions in the ongoing pandemic.

The collaborative effort between Zentek and McMaster University has led to a game-changing aptamer platform demonstrating impressive efficacy in neutralizing SARS-CoV-2 during pre-clinical trials. With the potential to serve as a therapeutic or prophylactic for COVID-19 and future variants, the aptamers shine a ray of hope in the global fight against the pandemic. The expanded license agreement opens doors for innovative applications in diagnostics and therapeutics, opening up possibilities for further advancements in medical science.

However, it is crucial to note that Zentek maintains caution and does not claim to have a product that can entirely eliminate, cure, or contain COVID-19 at this stage. Nevertheless, the progress achieved so far signifies a positive step in the race to combat this global health crisis. As further developments unfold, the world eagerly awaits the potential impact of Zentek’s aptamer platform in transforming the landscape of COVID-19 treatment and prevention. Stay tuned for more exciting updates as this remarkable journey continues to unfold.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified graphene technology company focused on the research, development and commercialization of graphene-based novel products seeking to give the Company’s commercial partners a competitive advantage by making their products better, safer, and greener.

Zentek’s patented technology platform ZenGUARD™, is shown to have 99% anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario. Zentek’s patent pending ZenARMOR™ technology platform is focused on corrosion protection applications.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].




Greg Fenton on the impact of Zentek’s HVAC Phase 2 Testing results on Air Filtration

In this InvestorIntel interview, Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about receiving the final report for Phase 2 testing of ZenGUARD™ for use in Heating, Ventilation and Air Conditioning (“HVAC”) filtration. Used as an antimicrobial coating, Greg discusses how ZenGUARD™ is a “best in class solution” to improve indoor air quality and remove pathogens from air, including SARS-CoV-2 (virus that causes COVID-19).

With ability to increase efficiency of a MERV 8 filter by almost 5 times, Greg discusses how ZenGUARD™ coating can be applied to existing HVAC filters without having to do any modification to the HVAC systems. Having shared the Phase 2 report with Federal and Provincial organizations, Greg goes on to provide an update on commercialization of ZenGUARD™ coated HVAC filters.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond.

Zentek’s patented ZenGUARD™ coating is shown to have 99% antimicrobial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC systems. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].




Greg Fenton of Zentek on its new mask manufacturing agreement and US interest in its HVAC filters

In this InvestorIntel interview, host Tracy Weslosky talks to Zentek Ltd.‘s (NASDAQ: ZTEK | TSXV: ZEN) CEO and Director Greg Fenton about its new mask manufacturing and packaging agreement and interest generated from a successful promotional tour in the USA.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Greg discusses how Zentek has entered into an agreement with long-established Viva Healthcare Packaging (Canada) Ltd. to manufacture and sell surgical masks enhanced with Zentek’s proprietary ZenGUARD antimicrobial coating. At the height of the pandemic Viva was producing over 20 million masks per month. “They’re big and well established with an existing distribution network,” Greg tells Tracy, “so it was absolutely a perfect partnership for us.”

Greg also talks about his recent visit to Washington, D.C., that included 14 meetings with members of the U.S. Congress, to discuss indoor air quality and Zentek’s ZenGUARD-coated HVAC filters. “We developed a lot of momentum there,” he says. He also talks about ongoing testing of their HVAC filters in real world environments, like classrooms. “The simplicity and elegance of our solution is it’s a passive solution that can be added to any existing system.”

Finally, Greg also talks about Zentek’s finances. “We did a significant capital raise at the beginning of this year and our treasury’s in an excellent position,” he tells Tracy, “but we’re being very judicious in our spending.”

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Zentek Ltd.

Zentek is an IP development and commercialization company focused on the research, development and commercialization of novel products using graphene and nanomaterials for use in the healthcare industry and beyond. Zentek’s proprietary ZenGUARD™ coating is patent-pending and shown to have 99% antimicrobial activity, including against COVID-19, for use in PPE and potentially HVAC systems and other industries. Zentek’s ZenGUARD™ production facility is located in Guelph, Ontario.

To know more about Zentek Ltd., click here

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].




Bristow goes with technology and selects the stock to watch in 2022

Welcome to 2022! I’m cautiously optimistic that this will be the year we get to put Covid in the rear-view mirror and get on with life without always waiting for the next shoe to drop (or a new variant to take hold). I’m happy to put 2021 in the history books and anticipate the bright future that could be. In that vein, I’d like to look ahead to what I think could be an exciting story for 2022. Now don’t get me wrong, I’m not saying this is my top pick or suggesting it will go up. This is simply my perspective on a company that has a lot going on that could be rewarded by the market this year.

The path of least resistance, after this week’s market action, would be to pick a uranium stock. Between how this group performed in 2021 and even more impressively, the first couple of trading days of 2022, it would certainly make for an easy article to write. I’m also a fan of junior base and precious metal mining companies, especially ones with plenty of results pending, but not today. The future is technology, so my exciting stock for 2022 is a technology company that posted a respectable 35% return in 2021 but is well positioned for 2022. It also happened to evolve out of a junior mining exploration company so it’s the best of both worlds.

If you haven’t figured out what company I’m talking about yet, it’s Zentek Ltd. (TSXV: ZEN), formerly known as ZEN Graphene Solutions Ltd. There is so much going on at Zentek it’s hard to know where to start. The Company currently describes itself as an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuard™, a patent-pending coating shown to have 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as products against infectious diseases. The Company also has an exclusive agreement to be the global commercializing partner for a newly developed aptamer-based rapid pathogen detection technology. But that’s just the tip of the iceberg in my opinion.

The near-term catalyst is all about the antimicrobial coating ZENGuardTM, which was developed as a virucidal graphene-oxide (“GO”) based compound to be applied as a coating onto fabrics, which included personal protective equipment such as face masks in an effort to increase protection afforded by such products. In September 2021 the Company received Health Canada approval for the sale of ZENGuard™ coated masks and entered into a binding definitive license and supply agreement with Trebor Rx Corp. for the supply of ZENGuard™ to coat face masks and potentially other health care products. To date, Trebor has purchased, and the Company has delivered, quantities of ZENGuard™ coating sufficient for the production of 10,000,000 masks currently done via third parties. However, development is underway of the Company’s industrial scale facility to produce ZENGuard™ and to coat materials. The Company anticipates assembly and installation of the industrial scale production equipment to be completed during Q1 2022, at which point production is expected to commence while commissioning, optimization and production ramp-up occurs over the following two to three months. Once this industrial process is in operation, the Company expects the production capacity of ZENGuard™ to increase significantly.

Zentek recently closed a bought deal public offering and a non-brokered private placement for aggregate proceeds of C$33 million to assist in the build out of their facility as well as research and development, acceleration of business growth opportunities and working capital. Other growth opportunities include the development of a new carbon-based nanotechnology-enhanced icephobic coating to reduce ice accretion. The Company anticipates applications for aircraft, wind turbines, ocean vessels, and building structures to increase safety and efficiency outcomes in ice-forming weather conditions. In late November Zentek announced it had been awarded an R&D test contract through the Innovation Solutions Canada Testing Stream to test ZENGuard™ coated HVAC filters with interest from 3 different units within the National Research Council of Canada. Other innovations include the development of a stable diesel fuel additive, which increased the performance of diesel fuel by up to 10% in initial testing.

There is an awful lot going on at Zentek so I would encourage you to go check out their website to learn more because I’ve only scratched the surface of this stock to watch in 2022. Granted it’s not a small cap with a market cap of roughly $466 million after the closing of the latest capital raise earlier this week. Nevertheless, there are plenty of near-term catalysts with having their own production facility operational in the next few months and some pretty creative and unique opportunities being developed to propel this Company into the future.




Greg Fenton on the significant medical market interest in Zentek’s ZENGuard™ nanotech coatings, plus its new carbon-based icephobic coating

In a recent InvestorIntel interview, Tracy Weslosky spoke with Greg Fenton, CEO and Director of Zentek Ltd. (TSXV: ZEN) about Zentek’s new icephobic coating to reduce ice accretion on surfaces, and about the significant market interest in their ZENGuard™ coating following its Health Canada approval.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg Fenton said that the company’s recent change of name from ZEN Graphene Solutions Ltd. to Zentek Ltd. reflects its evolution from a mining company to a technology company, developing intellectual properties. Having recently applied for an up listing to the Nasdaq, Greg said that Zentek is primarily focused on nanotechnology-enabled healthcare solutions,  and continues to develop intellectual properties for other industries as well.

To watch the full interview, click here.

About Zentek Ltd.

Zentek is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is currently focused on commercializing ZENGuardTM, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar coatings as pharmaceutical products against infectious diseases.The company also has an exclusive agreement to be the global commercializing partner for a newly developed, highly scalable, aptamer-based, rapid pathogen detection technology.

To learn more about Zentek Ltd., click here.

Disclaimer: Zentek Ltd. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain“forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken,  as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email [email protected].